Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer
Status:
Completed
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well Akt inhibitor MK2206 works in treating patients with
breast cancer cancer that has spread to other places in the body and usually cannot be cured
or controlled with treatment. Akt inhibitor MK2206 may stop the growth of tumor cells by
blocking some of the enzymes needed for cell growth.